Stem Cells in Vascular Remodeling

干细胞在血管重塑中的作用

基本信息

  • 批准号:
    8586190
  • 负责人:
  • 金额:
    $ 34.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-07 至 2017-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Cardiovascular diseases account for 40% of death in United States. Vascular diseases such as atherosclerosis and restenosis involve extensive vascular remodeling such as cell proliferation and migration in neointima. Vascular smooth muscle cells (SMCs) are a major cell type in the tunica media of vascular wall, and it is generally accepted that mature SMCs can de-differentiate into proliferative/synthetic phenotype during vascular remodeling. However, there is a lack of direct evidence that characterize the de-differentiation of mature SMCs in vitro and in vivo, and the relative contribution of SMCs and vascular stem cells to disease development has not been well elucidated. Here we aim to address this knowledge gap. Recently, we have identified a novel type of multipotent vascular stem cells (MVSCs) in the wall of blood vessels. MVSCs express transcriptional markers such as Sox10 and Sox17, and can differentiate into both proliferative/synthetic and mature SMCs. In addition, MVSCs can differentiate into several mesenchymal (chondrogenic, adipogenic and osteogenic) and neural (peripheral neuron and Schwann cell) lineages. By using DNA microarray analysis, we have also identified a potential MVSC surface marker that may regulate MVSC proliferation and migration. Furthermore, by using lineage tracing and biochemical analysis, we have shown that MVSCs outgrow SMCs in culture and that MVSCs become proliferative following vascular injury and contribute to neointima formation. Finally, we have isolated and characterized MVSCs from human atherosclerotic plaques, coronary artery, aorta and femoral artery. Based on our preliminary studies, we hypothesize that MVSC differentiation is a major source of proliferative/synthetic SMCs and contributes to neointima formation. To test our hypothesis, three Specific Aims are proposed: (1) Characterize MVSC markers and the relative contribution of MVSCs and mature SMCs to proliferative/synthetic SMCs in vitro by using lineage tracing models; (2) Determine the roles of MVSCs and mature SMCs in neointima formation following vascular injury in transgenic mouse models; (3) Characterize MVSCs in human arteries and atherosclerotic lesions. If accomplished, this work will break new grounds in vascular biology, and demonstrate the important role of MVSC differentiation in vascular remodeling and disease development. This work will also provide insight into the mechanisms of vascular remodeling and lead to the development of novel therapies for vascular diseases by using MVSC as a therapeutic target.
描述(由申请人提供):心血管疾病占美国死亡人数的40%。血管疾病如动脉粥样硬化和再狭窄涉及广泛的血管重塑,如新生内膜中的细胞增殖和迁移。血管平滑肌细胞(Vascular smooth muscle cells,SMC)是血管壁中膜图尼卡中的主要细胞类型,其通常是 接受成熟SMC在血管重塑期间可去分化为增殖/合成表型。然而,缺乏直接的证据表明,在体外和体内的成熟平滑肌细胞的去分化的特点,平滑肌细胞和血管干细胞的疾病发展的相对贡献还没有得到很好的阐明。在这里,我们的目标是解决这一知识差距。最近,我们在血管壁中发现了一种新型的多能血管干细胞(MVSC)。MVSC表达转录标记物,如Sox 10和Sox 17,并且可以分化成增殖/合成和成熟的SMC。此外,MVSC可以分化成几种间充质(软骨形成、脂肪形成和成骨)和神经(外周神经元和许旺细胞)谱系。通过使用DNA微阵列分析,我们还确定了一个潜在的MVSC表面标记,可能会调节MVSC的增殖和迁移。此外,通过使用谱系追踪和生物化学分析,我们已经表明MVSC在培养中比SMC长,并且MVSC在血管损伤后变得增殖并有助于新生内膜形成。最后,我们从人动脉粥样硬化斑块、冠状动脉、主动脉和股动脉中分离并鉴定了MVSC。基于我们的初步研究,我们假设MVSC分化是增殖/合成SMC的主要来源,并有助于新生内膜形成。为了验证我们的假设,提出了三个具体的目的:(1)通过使用谱系追踪模型来表征MVSC标记物以及MVSC和成熟SMC在体外增殖/合成SMC中的相对贡献;(2)在转基因小鼠模型中确定MVSC和成熟SMC在血管损伤后新生内膜形成中的作用;(3)表征人类动脉和动脉粥样硬化病变中的MVSC。如果完成,这项工作将在血管生物学方面开辟新的领域,并证明MVSC分化在血管重塑和疾病发展中的重要作用。这项工作也将提供深入了解血管重塑的机制,并导致通过使用MVSC作为治疗靶点开发血管疾病的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Song Li其他文献

Song Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Song Li', 18)}}的其他基金

Combination Therapy for Pancreatic Cancer
胰腺癌的联合治疗
  • 批准号:
    10581174
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
Nanoparticles-mediated combination therapy for breast cancer
纳米颗粒介导的乳腺癌联合疗法
  • 批准号:
    10617544
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
Mechanopriming for cell engineering
用于细胞工程的机械引发剂
  • 批准号:
    10737574
  • 财政年份:
    2023
  • 资助金额:
    $ 34.82万
  • 项目类别:
Multimodal wireless electrical stimulation for tissue regeneration
用于组织再生的多模式无线电刺激
  • 批准号:
    10615764
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10703786
  • 财政年份:
    2022
  • 资助金额:
    $ 34.82万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10281141
  • 财政年份:
    2021
  • 资助金额:
    $ 34.82万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10491279
  • 财政年份:
    2021
  • 资助金额:
    $ 34.82万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10687264
  • 财政年份:
    2021
  • 资助金额:
    $ 34.82万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10442707
  • 财政年份:
    2019
  • 资助金额:
    $ 34.82万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10202507
  • 财政年份:
    2019
  • 资助金额:
    $ 34.82万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.82万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了